✦ LIBER ✦

CU32-085 or MadoparR as initial treatment of Parkinson's Disease. A double blind controlled study

✍ Scribed by E. Dupont; B. Mikkelsen

Book ID: 114781743
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 135 KB
Volume: 69
Category: Article
ISSN: 0001-6314
DOI: 10.1111/j.1600-0404.1984.tb02380.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Selegiline as the primary treatment of P

Selegiline as the primary treatment of Parkinson's disease — a long-term double-blind study

✍ V. V. Myllylä; K. A. Sotaniemi; P. Hakulinen; O. Mäki-lkola; E. H. Heinonen 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 739 KB

Comparison of desipramine and citalopram

Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study

✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

A double-blind, placebo-controlled study

A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease

✍ Richard B. Dewey Jr; Demetrius M. Maraganore; J. Eric Ahlskog; Joseph Y. Matsumo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 677 KB

Nine patients with advanced levodopa-responsive Parkinson's disease were enrolled in a double-blind, placebo-controlled crossover trial of intranasal apomorphine as rescue therapy for parkinsonian off-states. Patients were assigned in random order to each of four possible combinations of apomorphine

A Double-Blind, Randomized, Placebo and

A Double-Blind, Randomized, Placebo and Active-Controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease

✍ Joaquim J. Ferreira; Olivier Rascol; Werner Poewe; Cristina Sampaio; José-Franci 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 347 KB

274 METHYLPHENIDATE FOR THE TREATMENT OF

274 METHYLPHENIDATE FOR THE TREATMENT OF GAIT IMPAIRMENT IN PARKINSON'S DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER STUDY (PRELIMINARY RESULTS)

✍ A. Espay; A. Kumar Dwivedi; J. Vaughan; S. Savage; A. Sahay; A. Duker; F. Revill 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients

✍ Fabrizio Stocchi; Rupam Borgohain; Marco Onofrj; Anthony H.V. Schapira; Mohit Bh 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 446 KB 👁 2 views

## Abstract Safinamide is an α‐aminoamide with both dopaminergic and nondopaminergic mechanisms of action evaluated as an add‐on to dopamine agonist (DA) therapy in early‐stage PD. In this 24‐week, double‐blind study, patients with early PD receiving a stable dose of a single DA were randomized to